Pathogens (Feb 2021)

YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity

  • Congrui Zhu,
  • Samir El Qaidi,
  • Peter McDonald,
  • Anuradha Roy,
  • Philip R. Hardwidge

DOI
https://doi.org/10.3390/pathogens10020253
Journal volume & issue
Vol. 10, no. 2
p. 253

Abstract

Read online

The type III secretion system effector proteins NleB and SseK are glycosyltransferases that glycosylate protein substrates on arginine residues. We conducted high-throughput screening assays on 42,498 compounds to identify NleB/SseK inhibitors. Such small molecules may be useful as mechanistic probes and may have utility in the eventual development of anti-virulence therapies against enteric bacterial pathogens. We observed that YM155 (sepantronium bromide) inhibits the activity of Escherichia coli NleB1, Citrobacter rodentium NleB, and both Salmonella enterica SseK1 and SseK2. YM155 was not toxic to mammalian cells, nor did it show cross-reactivity with the mammalian O-linked N-acetylglucosaminyltransferase (OGT). YM155 reduced Salmonella survival in mouse macrophage-like cells but had no direct impact on bacterial growth rates, suggesting YM155 may have utility as a potential anti-virulence inhibitor.

Keywords